10x Genomics, Inc.

TXG Nasdaq SEC CIK 1770787
Follow 10x Genomics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $150.7M +1.1% vs same quarter last year
Net income −$19.4M +29.3% vs same quarter last year
EPS, diluted −$0.15 +31.8% vs same quarter last year
Operating cash flow $15.8M −63.4% vs same quarter last year
Revenue by quarter
$165M
$154.9M
$172.9M
$149M
$166M
$150.8M
$151M
$150.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$1B−$500M$0$500M$1BFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$642.8M−$43.5M
FY24$610.8M−$182.6M
FY23$618.7M−$255.1M
FY22$516.4M−$166M
FY21$490.5M−$58.2M
FY20$298.8M−$542.7M
FY19$245.9M−$31.3M
FY18$146.3M−$112.5M
FY17$71.1M−$18.8M
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200%−100%0%100%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2569.1%−9.5%−6.8%
FY2467.9%−31.9%−29.9%
FY2366.2%−42.9%−41.2%
FY2276.7%−32.5%−32.1%
FY2184.9%−10.7%−11.9%
FY2080.4%−178.7%−181.6%
FY1975.2%−12.4%−12.7%
FY1880.4%−75.7%−76.9%
FY1785.1%−25.8%−26.4%
FY16---
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0$100M$200MFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$130.1M
FY24−$5.7M
FY23−$63.8M
FY22−$165.3M
FY21−$122.7M
FY20−$254.6M
FY19−$8.1M
FY18−$82.7M
FY17−$14.5M
FY16-
Net margin vs the sectorMedian of Technology companies filing with the SEC
  • 10x Genomics
  • Technology median
−200%−150%−100%−50%0%50%FY17FY19FY21FY23FY25
Show the numbers
Year10x GenomicsTechnology median
FY25−6.8%−2.3%
FY24−29.9%−5%
FY23−41.2%−6.7%
FY22−32.1%−4.4%
FY21−11.9%−1.7%
FY20−181.6%−3%
FY19−12.7%0%
FY18−76.9%0.8%
FY17−26.4%2%
FY16-2.3%